HeartFlow - Longview Acquisition SPAC Deal Called Off
HeartFlow Holding Inc and a special purpose acquisition company, Longview Acquisition Corp II (NYSE: LGV), have called off merger plans that would have taken the cardiac test company public.
HeartFlow described the move as a mutual decision a "result of current unfavorable market conditions."
Affiliates of Glenview Capital Management sponsored Longview.
When HeartFlow and Longview announced the SPAC deal plans in July 2021, the merger was valued at .4 billion, with an estimated $400 million in cash after closing.
HeartFlow anticipated $599 million of gross proceeds to accelerate the growth of its non-invasive, personalized cardiac tests.
The company's non-invasive HeartFlow FFRCT analysis uses artificial intelligence to create a personalized three-dimensional heart model.
Clinicians can use the model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients.
The company's HeartFlow Analysis is commercially available in the U.S., the U.K., Canada, Europe, and Japan.
Price Action: LGV shares closed 0.21% higher at $9.73 on Friday.
See more from Benzinga
CAR-T Player Arcellx Raises 3M Via Initial Public Offering, Opens Trading At
Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.